Andrew J. Jatis, PharmD (Twitter: @jatis_rx) reviews the pharmacology and drug characteristics of dalbavancin and oritavancin, describes current literature assessing the safety and efficacy of FDA approved and off-label indications for lipoglycopeptide use in clinical practice and discusses pharmacoeconomic implications of lipoglycopeptide use in clinical practice.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
